

1 **Flagellin-elicited adaptive immunity suppresses flagellated microbiota and vaccinates**
2 **against chronic inflammatory diseases**

3


4

Tran et al.


5

6

Supplementary Information




Supplemental Figure 1. Localization of the adaptive immune response induced by flagellin immunization. C57BL/6J Wild Type mice were purchased from The Jackson Laboratory and housed for two weeks before procedure in order to favor microbiota stabilization. Next, flagellin (10 μ g per mouse) was administered by intraperitoneal injections weekly for 9 weeks, while control mice received vehicle (PBS). Following euthanasia, intestinal contents were collected and analyzed for **(A)** anti-flagellin IgA and **(B)** anti-flagellin IgG using ELISA kits. Additionally, intestinal contents were analyzed for **(C)** fecal flagellin and **(D)** fecal LPS using HEK 293 cells expressing mTLR5 or mTLR4 measuring bioactive flagellin and lipopolysaccharide, respectively. Data are the means \pm S.E.M.. Significance was determined using *t*-test ($*p \leq 0.05$ $**p \leq 0.01$). ($N=4-5$ mice). Source data are provided as a Source Data file.




Supplemental Figure 2: Microbiota composition analysis in flagellin immunized vs. non-immunized mice. 4-week old C57BL/6J mice were immunized with flagellin (10 μ g per mouse) by intraperitoneal injections weekly for 9 weeks, while control mice received vehicle (PBS). Fecal microbiota composition was analyzed using Illumina sequencing of the V4 region of 16S rRNA genes. **(A)** Principal coordinates analysis (PCoA) of the weighted UniFrac distance matrix at day 56 (post-stabilization, post-immunization). **(B)** LEfSe analysis at day 56 reveals multiple bacterial groups altered by flagellin immunization compared to PBS treated mice.


A




B




C




D




Supplemental Figure 3: Functional consequences of flagellin immunization on the intestinal microbiota. 4-week old C57BL/6J mice were immunized with *Salmonella*-derived or *Bacillus*-derived flagellin (10 μ g per mouse) by intraperitoneal injections weekly for 9 weeks, while control mice received vehicle (PBS). **(A)** Western blot of fecal samples from PBS or *Salmonella*-derived flagellin treated mice using an anti-flagellin primary antibody. **(B)** Fecal anti-flagellin IgA and IgG quantification in mice treated with vehicle or *Bacillus*-derived flagellin. **(C)** Fecal flagellin and **(D)** fecal LPS were analyzed using HEK 293 cells expressing mTLR5 or mTLR4 measuring bioactive flagellin and lipopolysaccharide, respectively. Data are the means \pm S.E.M.. Significance was determined using *t*-test (* $p \leq 0.05$ ** $p \leq 0.01$ *** $p \leq 0.001$, n.s. indicates non-significant). ($N=4-5$ mice). Source data are provided as a Source Data file.




Supplemental Figure 4. Histopathological analysis of flagellin immunized and non-immunized μ MT mice. 4-8 week-old C57BL/6J, Wild Type (**A**) or μ MT (**B**), mice received either vehicle or 10 μ g of flagellin by intraperitoneal injections weekly for 9 weeks. Subsequently, animals were treated weekly for 4 weeks by 1 mg of anti-IL-10R antibody intraperitoneally to induce intestinal inflammation. Mice were euthanized and hematoxylin & eosin staining was performed on colonic sections. Representative images were selected from 1 animal per cage of (**A**) Wild Type and (**B**) μ MT mice.



Supplemental Figure 5. Histopathological analysis of flagellin immunized and non-immunized TCR β KO mice. 4-week old C57BL/6J TCR β KO (**A**) and Wild Type (**B**) mice were purchased from The Jackson Laboratory and housed for two weeks before procedure in order to favor microbiota stabilization. Subsequently, mice were treated with either flagellin (10 μ g per mouse), TNF- α (50 μ g/kg body weight), or Poly (I:C) (10 μ g/kg body weight) *via* intraperitoneal injections weekly for 9 weeks, while control mice received vehicle (PBS). Animals were then treated weekly for 4 weeks by 1 mg of anti-IL-10R antibody intraperitoneally to induce intestinal inflammation. Mice were euthanized and hematoxylin & eosin staining was performed on colonic sections. Representative images were selected from 1 animal per cage of (**A**) TCR β KO and (**B**) Wild Type mice.



Supplemental Figure 6: Flagellin immunization protects against spontaneous colitis in IL-10 KO mice. 6-8 week-old, IL-10 KO mice received either vehicle or 10 μ g of flagellin by intraperitoneal injections weekly for 17 weeks before euthanasia. **(A-B)** Fecal anti-flagellin IgA and IgG. **(C-D)** Day 112 serum anti-flagellin IgA and IgG. **(E)** Body weights were measured weekly and expressed as relative values, day 0 being define as 100%. **(F)** Spleen weight. **(G)** Colon length. **(H)** Colon weight/length ratio. **(I)** Colonic myeloperoxidase levels. **(J-L)** Correlation of colon length from IL-10 KO mice and Day 112 fecal IgA and IgG, and Day 112 serum IgA. Data are the means \pm S.E.M.. Significance was determined using linear regression analysis (for **J-L**, p values shown), *t*-test ($*p \leq 0.05$ $****p \leq 0.0001$), or using one-way ANOVA corrected for multiple comparisons with a Bonferroni test ($\#p \leq 0.05$ $###p \leq 0.001$ $####p \leq 0.0001$). ($N=9-13$). Source data are provided as a Source Data file.



Supplemental Figure 7: Flagellin shows repeated protection against anti-IL-10R treatment but does not confer protection against DSS induced acute intestinal inflammation. 8-week old, Wild Type C57BL/6J mice were purchased from The Jackson Laboratory and housed for two weeks before procedure in order to favor microbiota stabilization. Subsequently, flagellin (10 μ g per mouse) was administered by intraperitoneal injections weekly for 9 weeks, while control mice received vehicle (PBS). Subsequently, colitis was induced by either 4 weekly intraperitoneal injections of 1 mg anti-IL-10R antibody or by treatment with DSS diluted in the drinking water (2.5%). **(A)** Fecal flagellin quantified using HEK 293 cells expressing mTLR5. Body weights were measured weekly and expressed as relative values, **(B)** day -14 (pre-immunization) or **(C-D)** day 63 (post-immunization, pre colitis induction) being define as 100%. **(E)** Spleen weight. **(F)** Colon length. Data are the means \pm S.E.M.. Significance was determined using *t*-test ($*p \leq 0.05$ $**p \leq 0.01$) or using one-way ANOVA corrected for multiple comparisons with a Bonferroni test ($\#p \leq 0.05$). ($N=4-5$). Source data are provided as a Source Data file.